Key facts
- It has raised $165.0M; the latest was Early Stage VC ($165.0M) in Dec 2025.
- Notable investors include GV, Bain Capital Life Sciences, Pictet, Third Rock Ventures, QVT Family Office — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Syremis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Syremis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syremis Therapeutics
Operator of a biopharmaceutical company intended to develop novel medicines that address major unmet needs in mental health care. The company offers a neuropsychiatric drug pipeline rooted in emerging and clinically validated biology, such as muscarinic M1/M4 agonism and next-generation NMDA antagonism, enabling customers to access more effective and better-tolerated treatments for conditions like schizophrenia, major depressive disorder and bipolar depression, ultimately reducing disability, relapse rates and improving quality of life.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2025
- Website
- syremis.com/
- Ownership
- Privately Held (backing)
Syremis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syremis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syremis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.